Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation
OXFORD, United Kingdom and MARLBOROUGH, Mass., 2016-09-01 13:17 CEST (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC(Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that the U.S. Magistrate Judge in the Company’s patent infringement lawsuit against Qiagen, Inc., Quest Diagnostics, Inc. and Laboratory Corporation of America Holdings has issued a recommendation denying in substantial part the defendants’ motion to dismiss the Company’s claims. In issuing his recommendation, the magistrate judge stated, “At this early juncture, the Court concludes that thein vitroaspect of the plaintiff’s tuberculosis test is an ‘inventive concept’ because it improves on prior methods of detecting tuberculosis infection.” The magistrate judge’s recommendation should now allow the Company to press forward with its case against the three defendants, asserting infringement of its six patents relating to methods for diagnosing TB infection.
“We are encouraged by the magistrate judge’s recommendation as it affirms our belief that Qiagen’s TB tests, as well as the laboratories performing those tests, are infringing our patented intellectual property,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “We look forward to vigorously prosecuting our claims based upon our six patents through the next phases of discovery and trial.”
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions.
The Company's first product is the T-SPOT®.TBtest, which is used to test for tuberculosis infection. The T-SPOT.TBtest has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The company’s second product line is a range of assays for Tick-borne diseases, such as Lyme disease, obtained through the acquisition of Imugen, Inc in July 2016.
The T-SPOT.CMVtest and the T-SPOT.PRTtest are the Company's third and fourth products and part of a series of assays intended for the transplantation market. In addition to these four product lines, the Company has additional active development programs, each of which leverages our proprietary immunology platforms. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found atwww.oxfordimmunotec.com.
T-SPOT and theOxford Immunotec logoare trademarks ofOxford Immunotec Ltd.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0501
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Oxford Immunotec15.12.2017 22:06 | pressemeddelelse
Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit
Algeco Scotsman15.12.2017 21:34 | pressemeddelelse
Algeco Scotsman Announces Acquisition of Iron Horse Ranch
Elemica15.12.2017 13:57 | pressemeddelelse
Elemica Named to Food Logistics Top 100 List
GSV Asset Management14.12.2017 21:05 | pressemeddelelse
GSV Asset Management Announces Strategic Investment from HMC Capital-Led Group
TrueCommerce14.12.2017 19:30 | pressemeddelelse
TrueCommerce Datalliance Releases Third 2017 Update for Vendor Managed Inventory Platform
ATTO Technology, Inc.14.12.2017 18:39 | pressemeddelelse
ATTO announces support for Apple® Release of the new iMac Pro
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum